Clarifying the disruption of ovarian steroid synthesis enzymes, paving the way for precision treatment of polycystic ovary syndrome
Background
Polycystic Ovary Syndrome (PCOS) is the most common endocrine-metabolic disorder, affecting more than 10% of women of reproductive age. Hyperandrogenism, anovulation, and polycystic ovarian morphology are the main symptoms. This condition is not only a major cause of infertility but also carries a high risk of leading to systemic metabolic disorders such as type 2 diabetes and cardiovascular disease.
However, the existing medical community has focused only on the resulting phenomenon of hormonal imbalance. This has led to reliance on temporary treatments such as using birth control pills to artificially regulate menstrual cycles or administering metformin, a diabetes drug, to improve insulin resistance.
To fundamentally solve the disease, a microscopic approach is needed to elucidate why and how the hormone synthesis process within the ovaries is disrupted.
Key Findings
This study comprehensively analyzed the enzymatic regulation of steroid hormone synthesis (steroidogenesis) occurring in the ovarian tissue of PCOS patients. In particular, the molecular disruption mechanism that induces androgen overproduction and estrogen deficiency was identified.
Dysfunctional communication between theca cells and granulosa cells, which produce hormones in the ovary, is identified as a key driver of the disease. Under normal conditions, when theca cells produce an appropriate amount of androgens, granulosa cells receive them and convert them into estrogen. However, in PCOS, specific synthesis enzymes in theca cells are abnormally activated, resulting in an excessive outflow of androgens. This leads to the saturation of granulosa cell receptors, and the communication between the two cells is blocked, causing impaired folliculogenesis.
This enzymatic dysregulation exacerbates oxidative stress in the ovary and creates a vicious cycle that deepens insulin resistance at the cellular level. Notably, this mechanism operates very differently depending on the patient's clinical phenotype. For example, obese patients show a predominance of a metabolic pathway in which hyperinsulinemia stimulates androgen synthesis enzymes in theca cells. In contrast, lean patients tend to have enzyme disruption driven by an imbalance in neuroendocrine hormones. Significant differences in the concentration of proteins that regulate steroid synthesis pathways were also observed between ovulatory and anovulatory patients.
Significance and Prospects
The research team presented a direction for precision treatment tailored to the molecular physiological characteristics of the patient. Instead of prescribing general hormone inhibitors, the possibility of introducing enzyme-specific inhibitors that target and block only the specific enzymes that drive androgen overproduction is suggested. Furthermore, the study explored next-generation precision medicine strategies that fundamentally normalize abnormal enzyme expression in the ovary by combining gene editing technology with exosome-based delivery systems with high targeted delivery efficiency.
However, there are still barriers to overcome before these research findings can be translated into actual clinical practice. A standard diagnostic method must be established to rapidly and inexpensively analyze the complex multi-omics data of individual patients in the clinical setting. Furthermore, subsequent research is needed to demonstrate the long-term safety of targeted gene editing or exosome delivery technology in vivo.
Polycystic ovary syndrome (PCOS) is the most prevalent endocrine-metabolic disorder in women of reproductive age, and is characterized by hyperandrogenism, anovulation, and polycystic ovarian morphology. Emerging molecular evidence has identified dysregulated ovarian steroidogenesis as a major contributing mechanism linking reproductive and metabolic phenotypes in PCOS, acting in concert with neuroendocrine and metabolic dysfunction. This review synthesizes current knowledge on enzymatic and regulatory perturbations driving androgen excess and estrogen deficiency in PCOS, emphasizing their mechanistic, diagnostic, and therapeutic implications. Dysregulated steroidogenic enzymes and associated signaling pathways contribute to androgen excess, impaired folliculogenesis, and metabolic dysfunction in PCOS. Importantly, these steroidogenic alterations are not uniform across all patients with PCOS but vary according to hyperandrogenic, anovulatory, ovulatory, lean, obese, reproductive, and metabolic phenotypes. Particular focus is placed on how these molecular derangements disrupt theca-granulosa cell communication, impair folliculogenesis, and promote hyperandrogenism, oxidative stress, and insulin resistance in the ovaries. This review also discusses therapeutic strategies according to evidence level, distinguishing established PCOS treatments such as lifestyle intervention, insulin sensitizers, ovulation-induction agents, hormonal regulators, and anti-androgens from investigational enzyme-specific inhibitors and speculative precision approaches such as gene editing and exosome-based delivery systems. Collectively, these insights underscore that the pathophysiology of PCOS extends beyond endocrine imbalance to encompass multi-omic alterations in metabolism and signaling. Understanding enzyme-level dysregulation offers opportunities for mechanism-based interventions that can restore steroidogenic homeostasis, improve fertility outcomes, and mitigate long-term metabolic r
This study provides a concrete pathway for shifting the PCOS diagnosis and treatment paradigm in clinical practice from symptom management to cause-based treatment.
The most realistic scenario is personalized treatment based on each patient's molecular phenotype. For example, a PCOS patient visiting a hospital can undergo multiple analyses based on the presence of obesity, ovulation status, and hormone levels to identify their own type of pathogenesis. In obese patients, insulin sensitizers that normalize the metabolic pathway and block the stimulation of theca cells will be the mainstay. In contrast, in lean anovulatory patients, ovarian-targeted gene delivery exosomes can be administered to restore reproductive capacity safely by normalizing only the ovarian steroid enzyme activity within the normal range. These mechanism-based personalized interventions are expected to contribute significantly to reducing unnecessary hormone side effects and improving the success rate of infertility treatment.